Welcome to our dedicated page for Awakn Life Scien news (Ticker: AWKNF), a resource for investors and traders seeking the latest updates and insights on Awakn Life Scien stock.
Awakn Life Sciences Corp. news covers the company's historical role as a clinical-stage biotechnology issuer developing therapeutics for substance use and mental health disorders, with a near-term focus on Alcohol Use Disorder. Recurring updates included R&D programs such as AWKN-001 and AWKN-002, regulatory interactions, clinical-development planning, and financing arrangements supporting research activity.
The company's recent corporate news also documents its completed statutory arrangement and sale to Solvonis Therapeutics plc, including shareholder approval, supplemental disclosure tied to minority-securityholder protections, treatment of common shares and equity awards, and related warrant adjustments.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Revitalist Lifestyle and Wellness Ltd. (CSE: CALM, OTCQB: RVLWF) has entered into a licensing partnership with Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF) to implement the KARE® protocol for treating Alcohol Use Disorder. Awakn's ketamine-assisted therapy demonstrates significant improvements over current treatment standards, achieving an 86% abstinence rate in post-treatment trials. Revitalist will incur an annual licensing fee and share revenue from services. The U.S. alcohol treatment industry, worth over $30B, faces high relapse rates, which this partnership aims to address.